Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
de Braud
Filippo
F
De Pas
Tommaso
T
Spaggiari
Lorenzo
L
Veronesi
Giulia
G
Curigliano
Giuseppe
G
Noberasco
Cristina
C
Pelosi
Giuseppe
G
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D066246:ErbB Receptors / Q000235:genetics* / Q000378:metabolism; D000077156:Gefitinib; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D008198:Lymph Nodes / Q000378:metabolism; D008207:Lymphatic Metastasis; D009154:Mutation; D010766:Phosphorylation / Q000187:drug effects; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt; D011799:Quinazolines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D011518:Proto-Oncogene Proteins; D011799:Quinazolines; D066246:ErbB Receptors; C494918:AKT1 protein, human; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt; D000077156:Gefitinib